Reversible posterior leukoencephalopathy syndrome in cancer

Current Oncology Reports

Volumn 10, Issue 1, 2008, Pages 86-91

  Vaughn, Christopher ^a   Zhang, Louann ^b   Schiff, David ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; OXALIPLATIN; PREDNISONE; RAPAMYCIN; RITUXIMAB; SORAFENIB; TEMSIROLIMUS; UNINDEXED DRUG; VINCRISTINE;

ANEMIA; ARTERY DISEASE; B CELL LYMPHOMA; BILE DUCT CARCINOMA; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CLINICAL FEATURE; COLON CANCER; ENDOTHELIAL DYSFUNCTION; GLIOBLASTOMA; HODGKIN DISEASE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKOENCEPHALOPATHY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MICROANGIOPATHY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PROGNOSIS; RADIATION INJURY; RECTUM CANCER; REVIEW; STOMACH CANCER; TESTIS CANCER; THROMBOTIC THROMBOCYTOPENIC PURPURA; TROPHOBLASTIC TUMOR;

HUMANS; NEOPLASMS; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;

EID: 38149028284     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0013-z     Document Type: Review

References (34)

1. Hinchey J, Chaves C, Appignani B, et al.: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996, 334:494-500.
2. Glusker P, Recht L, Lane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354:980-981.
3. Magnano M, Bush T, Herrera I, et al.: Reversible posterior leukoencephalopathy in patients with systemic lupus erythematous. Semin Arthritis Rheum 2006, 35:396-402.
4. Govindarajan R, Adusumilli J, Baxter DL, et al.: Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006, 24:e48.
5. Stott V, Hurrell M, Anderson T, et al.: Reversible posterior leukoencephalopathy syndrome; a misnomer reviewed. Intern Med J 2005, 35:83-90.
6. Garg RK: Posterior leukoencephalopathy syndrome. Postgrad Med J 2001, 77:24-28.
7. Covarrubias D, Luetmer P, Campeau N: Posterior reversible encephalopatby syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 2002, 23:1038-1048.
8. Allen J, Adlakha A, Bergethon P: Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006, 63:1475-1478.
9. Norden A, Batchelor T: Reversible posterior leukoencephalopathy syndrome. Onkologie 2007, 30:90-91.
10. Sander T, Clayman D, Sanchez-Ramos L, et al.: Brain in eclampsia: MR imaging with clinical correlation. Radiology 1991, 180:475-478.
11. Strandgaard S, Paulson O: Cerebral autoregulation. Stroke 1994, 15:413-417.
12. Edvinsson L, Oman C, Sjoberg N: Autonomic nerves, mast cells, and amine receptors in human brain vessels. Brain Res 1976, 15:377-393.
13. Benigni A, Morigi M, Perico N, et al.: The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation 1992, 54:775-780.
14. Fogo A, Hakim R, Sugiura M, et al.: Severe endothelial injury in a renal transplant patient receiving cyclosporine. Transplantation 1990, 49:1190-1192.
15. Miyazaki Y, Tajima Y, Sodo K, et al.: Hodgkin's disease related central nervous system angiopathy presenting as reversible posterior leukoencephalopathy. Intern Med 2004, 43:900-901.
16. Rangi PS, Partridge W, Newlands ES, Waldman AD: Posterior reversible leukoencephalopathy syndrome: a possible late interaction between cytotoxic agents and general anesthesia. Neuroradiology 2005, 47:586-590.
17. Ozcan C, Wong SJ, Hari P: Reversible posterior leukoencephalopathy and bevacizumab. N Engl J Med 2006, 354:980-982.
18. Paul F, Aktas O, Dieste FJ, et al.: Reversible posterior leukoencephalopathy after chemotherapy with cisplatin and 5-FU [in German]. Nervenarzt 2006, 77:706-710.
19. Connolly RM, Doherty CP, Beddy P, O'Byrne K: Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer 2007, 56:459-463.
20. Haefner M, Siciliano R, Widmer L, et al.: Reversible posterior leukoencephalopathy after treatment of diffuse large B cell lymphoma. Onkologie 2007, 30:138-140.
21. Bauwens D, Hanston P, Laterre PF, et al.: Recurrent seizures and sustained encephalopathy associated with dimethylsulfoxide-preserved stem cell infusion. Leuk Lymphoma 2005, 46:1671-1679.
22. Zhang SZ, Wang ZH, Hu HS: Effect of intra-arterial perfusion of cisplatin combined with concomitant radiation therapy on the healing of microvasculature anastomoses: an experimental study in rabbits [in Chinese]. Shanghai Kou Qiang Yi Xue 2005, 14:490-494.
23. Ito Y, Arahata Y, Goto Y, et al.: CispIatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998, 19:415-417.
24. Walker RW, Rosenblum MK, Kempin SJ, Christian MC: Carboplatin associated thrombotic microangiopathic hemolytic anemia. Cancer 1989, 64:1017-1020.
25. Divix L, Libura M, Libura J, et al.: In vitro toxicity studies with mitomycin and bleomycin on endothelium cells. Anticancer Drugs 1997, 9:859-868.
26. Tam C, Galanos J, Seymour J, et al.: Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for malignancies. Am J Hematol 2004, 77:72-76.
27. Delanty N, Vaughan C, Frucht S, Stubgen P: Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology 1997, 49:686-689.
28. Irvin W, MacDonald G, Smith JK, Kim WY: Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol 2007, 11:2484-2485.
29. Bodkin C, Eidelman H: Sirolimus induced posterior reversible encephalopathy. Neurology 2007, 68:2039-2040.
30. Serkova N, Christian U, Flogel U, et al.: Assessment of the mechanism of astrocyte swelling induced by the macrolide immunosuppressant sirolimus using multinuclear nuclear magnetic resonance spectroscopy. Chem Res Toxicol 1997, 10:1359-1363.
31. Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 2007, 356:2271-2281.
32. Levine R, Karumanchi S: Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005, 48:372-386.
33. Motzer R, Bukowski R: Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006, 24:5601-5608.
34. Ledingham J, Rajagopalan B: Cerebral complications of accelerated hypertension. Q J Med 1979, 48:25-41.